Nitric oxide (SB 414)

Drug Profile

Nitric oxide (SB 414)

Alternative Names: SB414

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novan Inc
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifungals; Antihypertensives; Antipsoriatics; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Interleukin-17 inhibitors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Psoriasis
  • Preclinical Atopic dermatitis

Most Recent Events

  • 18 Oct 2017 Phase-Ib clinical trials in Psoriasis (Topical)
  • 18 Oct 2017 Novan plans a phase Ib trial for Atopic dermatitis before the end of 2017
  • 27 Apr 2017 Preclinical trials in Atopic dermatitis in USA prior to 27/04/2017 (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top